Stay updated on Pembrolizumab in NSCLC with PS 2 Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in NSCLC with PS 2 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the PePS2 pembrolizumab study is displayed, with details about its completed phase 2 trial in patients with non-small cell lung cancer and performance status 2. The record also includes study outcomes, eligibility criteria, publications, and participant-data sharing information.
    Difference
    54%
    Check dated 2026-11-08T03:08:55.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T23:19:57.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T23:23:38.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-17T23:41:39.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, while the study page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T23:38:37.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a simplified HTML structure and basic header/footer, replacing the previous study content and navigation with an access-restricted notice.
    Difference
    18%
    Check dated 2026-09-19T22:24:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in NSCLC with PS 2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.